Overview
Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2023-01-01
2023-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Lancaster General HospitalTreatments:
Pharmaceutical Solutions
Tranexamic Acid
Criteria
Inclusion Criteria:1. Provision of written informed consent
2. Age > or = to 65 years
3. Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric
regions
4. Indication for one of the following surgical interventions: hemiarthroplasty, total
hip replacement, sliding plate and screw fixation, or intramedullary fixation
Exclusion Criteria:
1. Indication for closed reduction or percutaneous screw
2. Allergy to TXA
3. Cerebrovascular accident/stroke, active coronary disease/myocardial infarction, or
deep vein thrombosis/pulmonary emboli within one (1) month of the fracture
4. Presence of hypercoaguable disorder